Fiche publication
Date publication
janvier 2022
Journal
Molecular & cellular oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
Tous les auteurs :
Ghiringhelli F
Lien Pubmed
Résumé
Resistance to chemoimmunotherapy is a major issue for cancer care. We recently unravelled the role of mitogen-activated protein kinase (MAPK) to limit the antitumor efficacy of such combination. Inhibitor of MAPK pathway using mitogen-activated protein kinase (MEK) inhibitor in combination with chemotherapy triggers mitophagy of cancer cells, which induces the release of mitochondrial DNA that interact with Toll Like receptor 9 (TLR9) to promote the production of the chemokine CXCL10. CXCL10 could then turn cold tumor into hot tumor, thus leading to improve efficacy of chemoimmunotherapy.
Mots clés
CXCL10, Lung cancer, MEK inhibitor, TLR9, chemotherapy, immunogenic cell death, immunotherapy, mitophagy
Référence
Mol Cell Oncol. 2022 ;9(1):2054652
